LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

Search

Maravai LifeSciences Holdings Inc (Class A)

Gesloten

2.29 4.57

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.18

Max

2.29

Belangrijke statistieken

By Trading Economics

Inkomsten

-6.4M

-53M

Verkoop

-9.6M

47M

EPS

-0.02

Winstmarge

-112.813

Werknemers

580

EBITDA

-28M

-49M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+147.5% upside

Dividenden

By Dow Jones

Volgende Winsten

6 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

18M

793M

Vorige openingsprijs

-2.28

Vorige sluitingsprijs

2.29

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

22 mei 2025, 23:48 UTC

Populaire aandelen

Stocks to Watch: Deckers Outdoor, Intuit, Ross Stores, Lightbridge, NuScale Power, Centrus Energy

22 mei 2025, 23:07 UTC

Top Nieuws

Fortescue Energy CEO to Resign in Executive Overhaul

22 mei 2025, 23:03 UTC

Belangrijke Marktbewegers

Nuclear-Industry Stocks Get Boost After Report Says Trump Will Sign Orders to Jumpstart Field

22 mei 2025, 23:59 UTC

Marktinformatie

Gold Edges Higher, Supported by Lingering Worries Over U.S. Deficits -- Market Talk

22 mei 2025, 23:45 UTC

Marktinformatie

Nikkei May Trade in Range as Uncertainty Over Tariffs Continues -- Market Talk

22 mei 2025, 23:45 UTC

Marktinformatie

Global Equities Roundup: Market Talk

22 mei 2025, 23:23 UTC

Marktinformatie

Global Energy Roundup: Market Talk

22 mei 2025, 23:23 UTC

Marktinformatie

Fortescue Iron Bridge Delay Disappoints; Executive Changes Welcomed -- Market Talk

22 mei 2025, 20:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

22 mei 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

22 mei 2025, 20:46 UTC

Acquisities, Fusies, Overnames

Alcon and Lensar Receive FTC Requests for Additional Information About Merger

22 mei 2025, 20:39 UTC

Winsten

Tesla's Emissions Credits Are at Risk After Senate's California Vote -- Barrons.com

22 mei 2025, 20:36 UTC

Top Nieuws

Antitrust Cops Say BlackRock, Other Fund Giants May Have Harmed Energy Competition -- 4th Update

22 mei 2025, 20:36 UTC

Top Nieuws
Winsten

Workday Logs Higher 1Q Revenue, Backs Outlook; Initiates $1B Buyback Program

22 mei 2025, 20:32 UTC

Top Nieuws
Winsten

Intuit Stock Rises After Earnings Grew More than Expected In Latest Tax Season -- Barrons.com

22 mei 2025, 20:27 UTC

Top Nieuws

Trump's 'Big, Beautiful Bill' Heads to Senate, Where New Fights Loom -- WSJ

22 mei 2025, 20:20 UTC

Top Nieuws

Bond Market Shows Signs of Stabilizing; Nasdaq Rises -- WSJ

22 mei 2025, 20:17 UTC

Top Nieuws

The Deficit Is Unsettling Bond Traders. Here's How That Affects the Economy. -- 2nd Update

22 mei 2025, 20:16 UTC

Winsten

Intchains Group 1Q Rev $18.2M >ICG

22 mei 2025, 20:15 UTC

Top Nieuws

Bond Market Shows Signs of Stabilizing; Nasdaq Rises -- WSJ

22 mei 2025, 20:08 UTC

Top Nieuws
Winsten

Intuit Stock Rises After Earnings Grew More than Expected In Latest Tax Season -- Barrons.com

22 mei 2025, 20:05 UTC

Top Nieuws

Intuit Seeing Stable Environment for Consumers, Businesses While Tariffs Play Out

22 mei 2025, 20:04 UTC

Winsten

Workday Sees FY26 Subscription Revenue $8.8B >WDAY

22 mei 2025, 20:04 UTC

Winsten

Workday Sees 2Q Subscription Revenue $2.16B >WDAY

22 mei 2025, 20:01 UTC

Winsten

Intuit Sees FY25 EPS $13.19-EPS $12.24 >INTU

22 mei 2025, 20:01 UTC

Winsten

Workday 1Q Net $68M >WDAY

22 mei 2025, 20:01 UTC

Winsten

Workday 1Q EPS 25c >WDAY

22 mei 2025, 20:01 UTC

Winsten

Workday 1Q Adj EPS $2.23 >WDAY

22 mei 2025, 20:01 UTC

Winsten

Workday 1Q Subscription Revenue $2.06B >WDAY

22 mei 2025, 20:01 UTC

Winsten

Workday 1Q Rev $2.24B >WDAY

Peer Vergelijking

Prijswijziging

Maravai LifeSciences Holdings Inc (Class A) Prognose

Koersdoel

By TipRanks

147.5% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 5.94 USD  147.5%

Hoogste 10 USD

Laagste 2 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Maravai LifeSciences Holdings Inc (Class A) - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

10 ratings

6

Buy

4

Hold

0

Sell

Technische score

By Trading Central

2.02 / 2.115Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

No Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.